Radiopharmaceutical deals drive sector growth despite supply crisis
A reinvigorated interest in radiopharmaceuticals has brought nuclear medicine to the foreground with deals over 2024 further exemplifying this trend. As revenues rose for Novartis’ radiopharmaceutical blockbuster Pluvicto, competitors are packing their …